3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
18
Carcinoma, Non-Small-Cell Lung
15
Lung Neoplasms
7
Breast Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Head and Neck Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Melanoma
1
Locally Advanced Pancreatic Cancer
1
Gastric Adenocarcinoma
1
Gallbladder Cancer Unresectable
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Brain Neoplasms
1
Anal Cancer Metastatic
1
Interventions
pembrolizumab
1
Paclitaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Non-small Cell Lung Cancer
×
130-nm albumin-bound paclitaxel
×
30 days
×
Clear all
NCT07221474
2026-05-28
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled